CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity

Journal of Immunology

Volumn 191, Issue 1, 2013, Pages 369-377

  Von Bauer, Rüdiger ^a,b   Oikonomou, Dimitrios ^a   Sulaj, Alba ^a   Mohammed, Sawsan ^a   Hotz Wagenblatt, Agnes ^c   Gröne, Hermann Josef ^c   Arnold, Bernd ^c   Falk, Christine ^d   Luethje, Dorit ^a   Erhardt, Axel ^a   Stern, David M ^e   Bierhaus, Angelika ^a   Nawroth, Peter P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADVANCED GLYCATION END PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN S100B; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENDOTHELIUM CELL; GENE DELETION; GENE SILENCING; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANIMALS; ANTIGENS, CD; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY, DELAYED; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE GROWTH FACTORS; PEPTIDES; S100 PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; UP-REGULATION;

EID: 84879616614     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201864     Document Type: Article

References (69)

1. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
2. Chin, A. I., P. W. Dempsey, K. Bruhn, J. F. Miller, Y. Xu, and G. Cheng. 2002. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416: 190-194. (Pubitemid 34246478)
3. Kobayashi, K., N. Inohara, L. D. Hernandez, J. E. Galán, G. Núñez, C. A. Janeway, R. Medzhitov, and R. A. Flavell. 2002. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194-199. (Pubitemid 34246479)
4. Saiga, H., Y. Shimada, and K. Takeda. 2011. Innate immune effectors in mycobacterial infection. Clin. Dev. Immunol. 2011: 347594.
5. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675-680. (Pubitemid 32747155)
6. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738. (Pubitemid 33009951)
7. Sorci, G., G. Giovannini, F. Riuzzi, P. Bonifazi, T. Zelante, S. Zagarella, F. Bistoni, R. Donato, and L. Romani. 2011. The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog. 7: e1001315.
8. Bianchi, M. E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81: 1-5. (Pubitemid 46028489)
9. Lotze, M. T., H. J. Zeh, A. Rubartelli, L. J. Sparvero, A. A. Amoscato, N. R. Washburn, M. E. Devera, X. Liang, M. Tör, and T. Billiar. 2007. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220: 60-81. (Pubitemid 350045579)
10. Foell, D., H. Wittkowski, T. Vogl, and J. Roth. 2007. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81: 28-37. (Pubitemid 46021248)
11. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195. (Pubitemid 34773774)
12. Ostendorp, T., E. Leclerc, A. Galichet, M. Koch, N. Demling, B. Weigle, C. W. Heizmann, P. M. Kroneck, and G. Fritz. 2007. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 26: 3868-3878. (Pubitemid 47295872)
13. Donato, R. 2007. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med. 7: 711-724.
14. Taguchi, A., D. C. Blood, G. del Toro, A. Canet, D. C. Lee, W. Qu, N. Tanji, Y. Lu, E. Lalla, C. Fu, et al. 2000. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360. (Pubitemid 30337069)
15. Dumitriu, I. E., P. Baruah, B. Valentinis, R. E. Voll, M. Herrmann, P. P. Nawroth, B. Arnold, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini. 2005. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174: 7506-7515. (Pubitemid 40806253)
16. van Zoelen, M. A., H. Yang, S. Florquin, J. C. Meijers, S. Akira, B. Arnold, P. P. Nawroth, A. Bierhaus, K. J. Tracey, and T. van der Poll. 2009. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31: 280-284.
17. Bucciarelli, L. G., T. Wendt, L. Rong, E. Lalla, M. A. Hofmann, M. T. Goova, A. Taguchi, S. F. Yan, S. D. Yan, D. M. Stern, and A. M. Schmidt. 2002. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 59: 1117-1128.
18. D'Agati, V., and A. M. Schmidt. 2010. RAGE and the pathogenesis of chronic kidney disease. Nat. Rev. Nephrol. 6: 352-360.
19. Yan, S. F., R. Ramasamy, and A. M. Schmidt. 2008. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 4: 285-293. (Pubitemid 351571138)
20. Ramasamy, R., S. F. Yan, and A. M. Schmidt. 2009. RAGE: therapeutic target and biomarker of the inflammatory response - the evidence mounts. J. Leukoc. Biol. 86: 505-512.
21. Andrassy, M., J. Igwe, F. Autschbach, C. Volz, A. Remppis, M. F. Neurath, E. Schleicher, P. M. Humpert, T. Wendt, B. Liliensiek, et al. 2006. Post-translationally modified proteins as mediators of sustained intestinal inflammation. Am. J. Pathol. 169: 1223-1237. (Pubitemid 351194359)
22. Sims, G. P., D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle. 2010. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28: 367-388.
23. Bierhaus, A., and P. P. Nawroth. 2009. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52: 2251-2263.
24. Riehl, A., J. Németh, P. Angel, and J. Hess. 2009. The receptor RAGE: Bridging inflammation and cancer. Cell Commun. Signal. 7: 12.
25. Bierhaus, A., S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Klöting, et al. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50: 2792-2808. (Pubitemid 33733131)
26. Hermani, A., B. De Servi, S. Medunjanin, P. A. Tessier, and D. Mayer. 2006. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp. Cell Res. 312: 184-197. (Pubitemid 41721180)
27. Liliensiek, B., M. A. Weigand, A. Bierhaus, W. Nicklas, M. Kasper, S. Hofer, J. Plachky, H. J. Gröne, F. C. Kurschus, A. M. Schmidt, et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113: 1641-1650. (Pubitemid 39071688)
28. Djuric, Z., M. Kashif, T. Fleming, S. Muhammad, D. Piel, R. von Bauer, F. Bea, S. Herzig, M. Zeier, M. Pizzi, et al. 2012. Targeting activation of specific NF-κB subunits prevents stress-dependent atherothrombotic gene expression. Mol. Med. 18: 1375-1386.
29. Chen, Y., E. M. Akirav, W. Chen, O. Henegariu, B. Moser, D. Desai, J. M. Shen, J. C. Webster, R. C. Andrews, A. M. Mjalli, et al. 2008. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181: 4272-4278.
30. Moser, B., D. D. Desai, M. P. Downie, Y. Chen, S. F. Yan, K. Herold, A. M. Schmidt, and R. Clynes. 2007. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J. Immunol. 179: 8051-8058.
31. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215: 403-410.
32. Womble, D. D. 2000. GCG: The Wisconsin Package of sequence analysis programs. Methods Mol. Biol. 132: 3-22.
33. Hotz-Wagenblatt, A., and W. Dröge. 2002. Redox-mediated functional and structural changes in insulin receptor kinase. Methods Enzymol. 348: 288-296.
34. Gotoh, O. 1996. Significant improvement in accuracy of multiple protein sequence alignments by iterative refinement as assessed by reference to structural alignments. J. Mol. Biol. 264: 823-838. (Pubitemid 27013563)
35. van Kilsdonk, J. W., N. Takahashi, U. Weidle, H. Burtscher, J. Jarry, M. R. Daha, G. W. Swart, and L. C. van Kempen. 2012. Modulation of activated leukocyte cell adhesion molecule-mediated invasion triggers an innate immune gene response in melanoma. J. Invest. Dermatol. 132: 1462-1470.
36. Wu, Y., Q. Li, and X. Z. Chen. 2007. Detecting protein-protein interactions by Far western blotting. Nat. Protoc. 2: 3278-3284.
37. Donato, R. 2001. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33: 637-668. (Pubitemid 32520962)
38. Foell, D., H. Wittkowski, and J. Roth. 2007. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 3: 382-390. (Pubitemid 47034539)
39. Yan, S. F., R. Ramasamy, Y. Naka, and A. M. Schmidt. 2003. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93: 1159-1169. (Pubitemid 37543056)
40. Prakken, B., S. Albani, and A. Martini. 2011. Juvenile idiopathic arthritis. Lancet 377: 2138-2149.
41. Cirillo, C., G. Sarnelli, G. Esposito, F. Turco, L. Steardo, and R. Cuomo. 2011. S100B protein in the gut: the evidence for enteroglial-sustained intestinal inflammation. World J. Gastroenterol. 17: 1261-1266.
42. Koch, M., S. Chitayat, B. M. Dattilo, A. Schiefner, J. Diez, W. J. Chazin, and G. Fritz. 2010. Structural basis for ligand recognition and activation of RAGE. Structure 18: 1342-1352.
43. Huttunen, H. J., J. Kuja-Panula, G. Sorci, A. L. Agneletti, R. Donato, and H. Rauvala. 2000. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem. 275: 40096-40105. (Pubitemid 32064635)
44. Cirillo, C, G. Sarnelli, G. Esposito, M. Grosso, R. Petruzzelli, P. Izzo, G. Cali, F. P. D'Armiento, A. Rocco, G. Nardone, T. Iuvone, L. Steardo, and R. Cuomo. 2009. Increased mucosal nitric oxide production in ulcerative colitis is mediated in part by the enteroglial-derived s100b protein. Neurogastroenterol. Motil. 21: 1209-e1112.
45. Esposito, G., C. Cirillo, G. Sarnelli, D. De Filippis, F. P. D'Armiento, A. Rocco, G. Nardone, R. Petruzzelli, M. Grosso, P. Izzo, et al. 2007. Enteric glial-derived S100B protein stimulates nitric oxide production in celiac disease. Gastroenterology 133: 918-925. (Pubitemid 47374127)
46. Leclerc, E., G. Fritz, M. Weibel, C. W. Heizmann, and A. Galichet. 2007. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 282: 31317-31331. (Pubitemid 350044892)
47. Thulin, E., T. Kesvatera, and S. Linse. 2011. Molecular determinants of S100B oligomer formation. PLoS ONE 6: e14768.
48. Hamed, S. A., Z. I. Selim, A. M. Elattar, Y. M. Elserogy, E. A. Ahmed, and H. O. Mohamed. 2012. Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis. Clin. Rheumatol. 31: 123-132.
49. Du Pasquier, R. A., S. Jilek, M. Kalubi, S. Yerly, C. A. Fux, C. Gutmann, A. Cusini, H. F. Günthard, M. Cavassini, and P. L. Vernazza; Swiss HIV Cohort Study. 2013. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 27: 203-210.
50. Steiner, J., S. Westphal, M. L. Schroeter, K. Schiltz, W. Jordan, U. J. Müller, H. G. Bernstein, B. Bogerts, R. E. Schmidt, and R. Jacobs. 2012. Increased S100B+ NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain Behav. Immun. 26: 564-567.
51. Miki, Y., Y. Gion, Y. Mukae, A. Hayashi, H. Sato, T. Yoshino, and K. Takahashi. 2013. Morphologic, flow cytometric, functional, and molecular analyses of S100B positive lymphocytes, unique cytotoxic lymphocytes containing S100B protein. Eur. J. Haematol. 90: 99-110.
52. de Souza, D. F., K. Wartchow, F. Hansen, P. Lunardi, M. C. Guerra, P. Nardin, and C. A. Gonçalves. 2013. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 43: 14-22.
53. de Souza, D. F., M. C. Leite, A. Quincozes-Santos, P. Nardin, L. S. Tortorelli, M. M. Rigo, C. Gottfried, R. B. Leal, and C. A. Gonçalves. 2009. S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway. J. Neuroimmunol. 206: 52-57.
54. Sedaghat, F., and A. Notopoulos. 2008. S100 protein family and its application in clinical practice. Hippokratia 12: 198-204.
55. Rothermundt, M., M. Peters, J. H. Prehn, and V. Arolt. 2003. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 60: 614-632.
56. El-Osta, A., D. Brasacchio, D. Yao, A. Pocai, P. L. Jones, R. G. Roeder, M. E. Cooper, and M. Brownlee. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205: 2409-2417.
57. Nawroth, P. 2012. Innovative models for investigation of pathomechanisms leading to late diabetic complications. Exp. Clin. Endocrinol. Diabetes. 120: 177-178.
58. Rudnicki, M. A., P. N. Schnegelsberg, R. H. Stead, T. Braun, H. H. Arnold, and R. Jaenisch. 1993. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75: 1351-1359. (Pubitemid 24021909)
59. Zeisberg, M., M. Khurana, V. H. Rao, D. Cosgrove, J. P. Rougier, M. C. Werner, C. F. Shield, III, Z. Werb, and R. Kalluri. 2006. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med. 3: e100.
60. Carracedo, A., L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, A. Alimonti, A. Egia, A. T. Sasaki, G. Thomas, S. C. Kozma, et al. 2008. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118: 3065-3074.
61. Weih, F., G. Warr, H. Yang, and R. Bravo. 1997. Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 158: 5211-5218. (Pubitemid 127681224)
62. Condie, B. G., and M. R. Capecchi. 1994. Mice with targeted disruptions in the paralogous genes hoxa-3 and hoxd-3 reveal synergistic interactions. Nature 370: 304-307. (Pubitemid 24250127)
63. Yan, S. S., Z. Y. Wu, H. P. Zhang, G. Furtado, X. Chen, S. F. Yan, A. M. Schmidt, C. Brown, A. Stern, J. LaFaille, et al. 2003. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med. 9: 287-293. (Pubitemid 36362783)
64. Cayrol, R., K. Wosik, J. L. Berard, A. Dodelet-Devillers, I. Ifergan, H. Kebir, A. S. Haqqani, K. Kreymborg, S. Krug, R. Moumdjian, et al. 2008. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 9: 137-145.
65. Wagner, M., A. Wiśniewski, M. Bilińska, A. Pokryszko-Dragan, I. Nowak, P. Kuśnierczyk, and M. Jasek. 2013. ALCAM - Novel multiple sclerosis locus interfering with HLA-DRB1&z.ast;1501. J. Neuroimmunol. 258: 71-76 .
66. Levesque, M. C., C. S. Heinly, L. P. Whichard, and D. D. Patel. 1998. Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum. 41: 2221-2229. (Pubitemid 29009381)
67. Ikeda, K., and T. Quertermous. 2004. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J. Biol. Chem. 279: 55315-55323. (Pubitemid 40066529)
68. King, J. A., F. Tan, F. Mbeunkui, Z. Chambers, S. Cantrell, H. Chen, D. Alvarez, L. A. Shevde, and S. F. Ofori-Acquah. 2010. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. Mol. Cancer 9: 266.
69. Harrison, D. K., V. A. Spence, J. S. Beck, J. G. Lowe, and W. F. Walker. 1986. pH changes in the dermis during the course of the tuberculin skin test. Immunology 59: 497-501. (Pubitemid 17178269)